Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 941

1.

The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis.

Kahal H, Kyrou I, Uthman OA, Brown A, Johnson S, Wall PDH, Metcalfe A, Parr DG, Tahrani AA, Randeva HS.

Sleep Breath. 2019 May 20. doi: 10.1007/s11325-019-01835-1. [Epub ahead of print] Review.

PMID:
31111411
2.

The effects of exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: protocol for a systematic review and meta-analysis.

Woodward A, Klonizakis M, Lahart I, Carter A, Dalton C, Metwally M, Broom D.

Syst Rev. 2019 May 16;8(1):116. doi: 10.1186/s13643-019-1030-8.

3.

Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study.

Morotti E, Giovanni Artini P, Persico N, Battaglia C.

Gynecol Endocrinol. 2019 May 12:1-8. doi: 10.1080/09513590.2019.1613361. [Epub ahead of print]

PMID:
31081406
4.

Prevalence of Dyslipidaemia and Pre-Diabetes Among Women with Polycystic Ovary Syndrome (PCOS): Do We Overestimate Cardiovascular Risk?

Lewandowski KC, Płusajska J, Horzelski W, Lewiński A.

Horm Metab Res. 2019 May 10. doi: 10.1055/a-0896-4144. [Epub ahead of print]

PMID:
31075796
5.

Endogenous sex hormones and risk of venous thromboembolism in young women.

Scheres LJJ, van Hylckama Vlieg A, Ballieux BEPB, Fauser BCJM, Rosendaal FR, Middeldorp S, Cannegieter SC; CREW consortium.

J Thromb Haemost. 2019 May 4. doi: 10.1111/jth.14474. [Epub ahead of print]

PMID:
31054196
6.

Are there differences in basal thrombophilias and C-reactive protein between women with or without PCOS?

Sánchez-Ferrer ML, Prieto-Sánchez MT, Corbalán-Biyang S, Mendiola J, Adoamnei E, Hernández-Peñalver AI, Carmona-Barnosi A, Salido-Fiérrez EJ, Torres-Cantero AM.

Reprod Biomed Online. 2019 Feb 27. pii: S1472-6483(19)30103-8. doi: 10.1016/j.rbmo.2019.01.013. [Epub ahead of print]

PMID:
31023609
7.

Male PCOS equivalent and nutritional restriction: Are we stepping forward?

Di Guardo F, Cerana MC, D'urso G, Genovese F, Palumbo M.

Med Hypotheses. 2019 May;126:1-3. doi: 10.1016/j.mehy.2019.03.003. Epub 2019 Mar 5.

PMID:
31010486
8.

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome.

Dawson AJ, Sathyapalan T, Vince R, Coady AM, Ajjan RA, Kilpatrick ES, Atkin SL.

Front Endocrinol (Lausanne). 2019 Apr 2;10:189. doi: 10.3389/fendo.2019.00189. eCollection 2019.

9.

Peroxiredoxin 4 levels in patients with PCOS and/or obesity.

Gateva AT, Velikova TV, Kamenov ZA.

J Gynecol Obstet Hum Reprod. 2019 Apr 11. pii: S2468-7847(19)30034-0. doi: 10.1016/j.jogoh.2019.04.002. [Epub ahead of print]

PMID:
30980996
10.

[Sex and gender-specific aspects in prediabetes and diabetes mellitus-clinical recommendations (Update 2019)].

Kautzky-Willer A, Harreiter J, Abrahamian H, Weitgasser R, Fasching P, Hoppichler F, Lechleitner M.

Wien Klin Wochenschr. 2019 May;131(Suppl 1):221-228. doi: 10.1007/s00508-018-1421-1. German.

PMID:
30980153
11.

Biomarkers of Endothelial Dysfunction in Women With Polycystic Ovary Syndrome.

Dambala K, Paschou SA, Michopoulos A, Siasos G, Goulis DG, Vavilis D, Tarlatzis BC.

Angiology. 2019 Apr 10:3319719840091. doi: 10.1177/0003319719840091. [Epub ahead of print]

PMID:
30969784
12.

Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome.

Dahan MH, Reaven G.

Endocrine. 2019 Mar 21. doi: 10.1007/s12020-019-01899-9. [Epub ahead of print]

PMID:
30900204
13.

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.

Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, Khan AY, Kilpatrick ES, Atkin SL, Sathyapalan T.

Clin Endocrinol (Oxf). 2019 Jun;90(6):805-813. doi: 10.1111/cen.13968. Epub 2019 Apr 2.

PMID:
30866088
14.

Androgens drive microvascular endothelial dysfunction in women with polycystic ovary syndrome: role of the endothelin B receptor.

Usselman CW, Yarovinsky TO, Steele FE, Leone CA, Taylor HS, Bender JR, Stachenfeld NS.

J Physiol. 2019 Mar 7. doi: 10.1113/JP277756. [Epub ahead of print]

PMID:
30847930
15.

ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome.

Marchesan LB, Spritzer PM.

Fertil Steril. 2019 Mar;111(3):579-587.e1. doi: 10.1016/j.fertnstert.2018.11.034.

PMID:
30827526
16.

Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome.

Alalami H, Sathyapalan T, Atkin SL.

Ther Adv Endocrinol Metab. 2018 Nov 6;10:2042018818805674. doi: 10.1177/2042018818805674. eCollection 2019. Review.

17.
18.

Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis.

Kite C, Lahart IM, Afzal I, Broom DR, Randeva H, Kyrou I, Brown JE.

Syst Rev. 2019 Feb 12;8(1):51. doi: 10.1186/s13643-019-0962-3.

19.

Androgens and Blood Pressure Control: Sex Differences and Mechanisms.

Reckelhoff JF.

Mayo Clin Proc. 2019 Mar;94(3):536-543. doi: 10.1016/j.mayocp.2018.11.016. Epub 2019 Jan 31. Review.

PMID:
30713048
20.

Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.

Kazemi M, Pierson RA, Lujan ME, Chilibeck PD, McBreairty LE, Gordon JJ, Serrao SB, Zello GA, Chizen DR.

J Obstet Gynaecol Can. 2019 Jan 31. pii: S1701-2163(18)30991-5. doi: 10.1016/j.jogc.2018.11.026. [Epub ahead of print]

PMID:
30712903

Supplemental Content

Loading ...
Support Center